Drugs / aganirsen
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07411755 | Mar → Sep 2026 expected | atopic eczema | Jiangsu Genscend Biopharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02947867 | Jan 2017 → Jun 2019 | central retinal vein occlusion, neovascular glaucoma | Gene Signal SAS | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07386743 | Feb 2026 → Apr 2027 expected | atopic eczema | Jiangsu Genscend Biopharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aganirsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02947867 ↗ |
| Known as | GS101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07386743 ↗ |
| Action | Inhibit | “by blocking insulin receptor substrate-1 (IRS)-1” PMID 28302155 ↗ Mar 2017 |
| Route | Topical | “topical administration” PMID 28302155 ↗ Mar 2017 |
| Target | IRS1 | “by blocking insulin receptor substrate-1 (IRS)-1” PMID 28302155 ↗ Mar 2017 |